Latest 10-K annual reports

Tempest Therapeutics closed a share-funded CAR‑T asset deal, reported striking early multiple myeloma data, and outlined 2026 milestones, but flagged a going‑concern risk with just $7.7M in cash and reliance on an uncertain funding commitment.

Allurion secured FDA PMA approval for its swallowable gastric balloon but reported a 53% revenue decline, going‑concern doubts, NYSE delisting proceedings, and tight liquidity as it restructures and pursues financings.

MeiraGTx reported $81.4M in 2025 revenue driven by a $75M Lilly upfront, narrowed its net loss to $114.2M, secured FDA Breakthrough for its xerostomia gene therapy, and extended liquidity into H2 2027 pending a $200M Hologen collaboration closing in Q2 2026.

Ondas Inc. posted an 8.5x jump in 2025 revenue to $50.7M, closed multiple acquisitions, raised over $800M, ended with $594M cash, and reported a $133.4M net loss driven partly by a large warrant liability.

Scienture Holdings reported a $41.5M FY25 loss amid $26.3M impairments, launched FDA‑approved ARBLI and secured U.S. rights to 10mg naloxone nasal spray REZENOPY.

Vor Biopharma refocused on autoimmune drug telitacicept, advanced two global Phase 3 trials, reported a $696.0M 2025 net loss driven by a $222.6M license charge and warrant revaluation, and announced a $75.0M private placement to extend cash runway into early 2029.

Entrepreneur Universe Bright Group grew revenue 7.7% and net income 28% in 2025, tightened cash to $11.0M, executed a 1-for-10 reverse split, and bought a Hong Kong money lender to enter fintech.

USA Rare Earth reported minimal 2025 revenue, a $298.5 million net loss, closed key acquisitions, commissioned initial U.S. magnet capacity, and signed a $1.6 billion U.S. government LOI while raising $1.5 billion in January 2026.

Aura Biosciences reports a wider 2025 net loss, substantial doubt about going concern, active late‑stage bel-sar program under SPA, and recent/warranted financings to extend runway.

Eikon Therapeutics reported a larger 2025 net loss while advancing its oncology pipeline, closing a $349M IPO in February 2026 and guiding cash runway into 2H 2027 despite a disclosed material weakness and a license dispute.

SportsQuest reported no revenue, a $121,640 net loss, $259 year-end cash, and a working capital deficit while relying on convertible notes to fund operations.

Neumora outlined multiple 2026 readouts, detailed loan and ATM financing activity, and reported a $236.9M 2025 net loss with $182.5M in year-end cash as it advances MDD, Alzheimer’s agitation, schizophrenia and obesity programs.

CytoSorbents grew 2025 revenue 4% and improved margins but flagged going concern risks, Nasdaq noncompliance, and a reset FDA path for DrugSorb-ATR after a 2025 De Novo denial.

PMGC Holdings reported $0.59M in first-year operating revenue and a $7.75M net loss, executed dilutive financings backed by pledged subsidiaries, and plans to advance lead biotech asset EL-22 toward a U.S. IND in 2026.

Greenpro Capital’s 2025 revenue fell 41% and net loss deepened to $3.0M, as auditors raised substantial doubt about its ability to continue as a going concern and the company moved to issue 8.5M shares for a Forekast stake.

Unicycive’s 10-K details a manufacturing-related FDA delay for oxylanthanum carbonate, a resubmitted NDA with a June 29, 2026 PDUFA, strengthened cash via ATM offerings, and new shareholder litigation.

AIxCrypto Holdings reported a $17.0M 2025 net loss, rebranded from Qualigen, raised $41M, built a $10.3M crypto treasury, and narrowed its strategy to real‑world asset tokenization and embodied AI while warning of going concern risks and heavy dilution.

American Picture House Corporation’s 2025 10-K shows sharply higher revenue, a smaller net loss, new revenue waterfalls on released films, and fresh financing lines, but flags going concern risks and potential dilution.

CitroTech Inc. reported 2025 revenue up 195% to $2.38M, heavy stock-based charges driving a $36.8M net loss, new NYSE listing, and multiple financings to fund growth through 2026.

HyOrc posted sharply lower 2025 revenue amid a plant shutdown and legal dispute, added methanol JV and project agreements, and flagged going-concern and funding needs.

Perimeter Acquisition Corp. I filed its 2025 Form 10-K, detailing $247.75 million held in trust, no target selected yet, and a defense-focused deal mandate with a 24‑month completion window.

Picard Medical posted a larger 2025 net loss amid modest revenue growth, completed a $19.6M IPO and issued $15M of senior secured notes with attached warrants as auditors flagged going-concern risk.

Soluna reported lower 2025 revenue and a wider net loss but ended the year with $76.4M cash, secured new project financing, advanced key data centers, and added a $250M equity facility in March 2026.

AIM ImmunoTech's 2025 annual report highlights a strategic pivot to late-stage pancreatic cancer for Ampligen, despite ongoing financial losses and NYSE American delisting concerns.

Space Asset Acquisition Corp. (SAAQ) filed its annual 10-K, outlining its blank check company structure, IPO details, and strategy to acquire a business in the global space economy.

Immix Biopharma, Inc. filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the auditor report date, while revealing significant capital raises and increased liquidity despite growing net losses.

Gesher Acquisition Corp. II, a SPAC, reported a net income of $3.47 million for 2025, driven by interest income, but faces substantial doubt about its ability to continue as a going concern without completing a business combination by December 2026.

K&F Growth Acquisition Corp. II, a SPAC, reported a net income of $10.2 million for 2025, primarily from trust account interest, but faces substantial doubt about its ability to continue as a going concern without a business combination by November 2026.

Enveric Biosciences, a biotechnology company, reported substantial doubt about its ability to continue as a going concern despite recent capital raises, as it focuses on preclinical development of its lead neuroplastogen candidate, EB-003.

SKYX Platforms Corp. filed an amended annual report for fiscal year 2025, primarily to correct an auditor report date, while highlighting ongoing liquidity challenges and recent capital raises.